CRP and COVID-19: Furthermore, reducing circulating pCRP levels via CRP apheresis using PC‐linked resins is currently being investigated with promising initial results as an adjunct therapy to minimize cardiac injury in patients with myocardial infarction (Ries et al, 2019, 2021) and COVID‐19 (Pepys, 2021; Ringel et al, 2021; Schumann et al, 2021; Torzewski et al, 2021; Esposito et al, 2022).